Regulatory Roundup for the Week of February 4, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup for the Week of February 4, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has released Guidance on Photosafety Evaluation of Pharmaceuticals S10, Step 2 Version (Nov. 13, 2012). This guidance recommends international standards for photosafety assessment, and harmonization of such assessments supporting human clinical trials and marketing authorization for pharmaceuticals.

In the effort to resolve the shortage of the cancer drug Doxil, FDA has approved the generic version of doxorubicin hydrochloride liposome injection, made by Sun Pharma Global FZE (Sun).

The European Medicines Agency and the Japanese Ministry of Health, Labour and Welfare (MHLW) have launched a public consultation on a joint reflection paper on the development of block-copolymer-micelle medicinal products.

The United States Pharmacopeia has announced the formation of three new Expert Committees for its Medicines Compendium (MC) and an expanded and enhanced website for the online-only compendium in response to the need for global public quality standards for medicines.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) launched a public health campaign in partnership with pharmacy organizations to promote the need for the public reporting of suspected side effects from drugs through MHRA’s Yellow Card Scheme.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here